NCT06826885 Safety and Efficacy of IMPT or IMRT for Breast Cancer
| NCT ID | NCT06826885 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2029-11-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The purpose of this trial is to compare the toxicities and efficacy of intensity-modulated proton therapy (IMPT) and intensity-modulated radiation therapy (IMRT) for breast cancer patients indicated for radiotherapy including preoperative radiotherapy, postoperative radiotherapy, or definitive radiotherapy. IMPT or IMRT will be administered to the whole breast, chest wall, and/or regional lymph nodes. A boost dose will be delivered in patients with high-risk area, at the discretion of the radiation oncologist. Eligible breast cancer patients will be followed for at least 5 years to assess acute and late radiation induced toxicities, loco-regional recurrence, overall survival, distant metastasis, and quality of life.
Eligibility Criteria
Inclusion Criteria * Aged ≥18 years old * Karnofsky Performance Status (KPS) score ≥70 * Histologically confirmed breast cancer with indications for preoperative radiotherapy, postoperative radiotherapy, or definitive radiotherapy as determined by the treating physician. * ER (estrogen-receptor), PR (progesterone-receptor), HER2 (human epidermal growth factor receptor 2), and Ki67 testing must be performed on the primary breast tumor. * Women of child-bearing potential must agree to use adequate contraception starting 1 month before study treatment and throughout the duration of study participation. * Ability to understand and willingness to participate in the research and sign the informed consent form. Exclusion Criteria * Pregnant or lactating women. * Severe non-neoplastic medical comorbidities that may interfere with treatment or study participation. * Active collagen vascular disease or other autoimmune disorders that could significantly increase the risk of radiation toxicity. *
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.